Prostate (Non-Cancer)

Non-cancer prostate conditions are the larger half of the BVA's prostate caseload. Across our analysis, 960 cases involve a non-cancer prostate condition as the primary issue, substantially more than the 597 cases tagged specifically as prostate cancer. The grant rate is 48.1 percent, comparable to the cancer subset. But the rating math, the presumptive framework, and the diagnostic codes are different in ways that matter for claim strategy.

The most common non-cancer prostate conditions claimed at the VA are benign prostatic hypertrophy (BPH), chronic prostatitis, and prostatic dysfunction. These all rate under DC 7527 ("Prostate gland injuries, infections, hypertrophy, postoperative residuals") in the genitourinary chapter at 38 CFR § 4.115b. The diagnostic code itself doesn't have an independent rating ladder. It tells the rater to look at the genitourinary symptoms the prostate condition is producing and rate under whichever symptom category is predominant: voiding dysfunction, urinary tract infection, or urinary frequency.

That structural feature shapes how most non-cancer prostate claims actually get decided. The diagnosis is the easy part. The fight is over which symptom code applies and what tier it supports.

TL;DR

• 960 non-cancer prostate cases in our BVA dataset. Outcomes: 48.1% granted, 38.5% denied, 13.3% remanded.
• DC 7527 rates non-cancer prostate conditions by analogy through 38 CFR § 4.115a, which sets the genitourinary residuals criteria. Voiding dysfunction, urinary frequency, and urinary tract infection are the three primary rating bases.
• Presumptive service connection grants at 57.9% (399 cases). Direct service connection grants at 47.5% (444 cases). Secondary grants at 35.8% (53 cases).
• The Agent Orange and PACT Act presumptions don't list BPH or chronic prostatitis directly, but the herbicide framework covers prostate cancer (304 cases in our presumptive subset), and the line between cancer and severe non-cancer prostate conditions can be procedurally significant.
• Camp Lejeune contaminated water (40 cases in our presumptive subset) covers certain bladder and urinary conditions that intersect with non-cancer prostate symptoms.
• "Severity insufficient" is the top denial reason at 135 of 370 classified denials. The rating typically lands at 0, 10, or 20 percent for BPH, with higher tiers reserved for cases with documented incontinence or repeated infections.
• Strong nexus opinions grant at 95.3 percent. Weak nexus grants at 0 percent. The opinion-quality cliff is steep, and the direct-lane cases that win almost always have specific nexus development.

DC 7527 and the Symptom-Code Routing Problem

DC 7527 is unusual in the rating schedule because it doesn't tell the rater what percentage to assign. It tells the rater where to look.

The regulatory text:

"Prostate gland injuries, infections, hypertrophy, postoperative residuals: Rate as voiding dysfunction or urinary tract infection, whichever is predominant."

That's the whole code. Three words of substantive content: rate by analogy. The actual rating depends on which symptom dominates the clinical picture.

The genitourinary residuals criteria at 38 CFR § 4.115a establish three primary symptom categories:

Voiding dysfunction

This is the rating category for veterans with documented urinary leakage, incontinence, or the need for absorbent materials. The ladder runs:

• 20%: Requiring the wearing of absorbent materials which must be changed less than 2 times per day
• 40%: Requiring the wearing of absorbent materials which must be changed 2 to 4 times per day
• 60%: Requiring the use of an appliance or the wearing of absorbent materials which must be changed more than 4 times per day

Voiding dysfunction is the predominant residual after prostate surgery (including TURP for BPH or radical prostatectomy in cancer cases) and is the most common rating basis for veterans with severe BPH or post-surgical complications.

Urinary frequency

This is the rating category for veterans with documented urinary frequency without significant incontinence. The ladder runs:

• 10%: Daytime voiding interval between 2 and 3 hours, or; awakening to void 2 times per night
• 20%: Daytime voiding interval between 1 and 2 hours, or; awakening to void 3 to 4 times per night
• 40%: Daytime voiding interval less than 1 hour, or; awakening to void 5 or more times per night

Many veterans with mild to moderate BPH or chronic prostatitis land here. The 10 percent and 20 percent tiers are the modal outcomes for non-surgical BPH claims.

Urinary tract infection

This is the rating category for veterans with documented recurrent prostatic or urinary tract infections. The ladder runs:

• 10%: Long-term drug therapy, 1-2 hospitalizations per year and/or requiring intermittent intensive management
• 30%: Recurrent symptomatic infection requiring drainage/frequent hospitalization (greater than 2/year), and/or requiring continuous intensive management

The infection-based rating is less commonly used for non-cancer prostate cases but applies to veterans with chronic bacterial prostatitis or chronic UTI patterns documented in the medical record.

What Wins on the Presumptive Lane

The 399 presumptive-category cases in our dataset break down across several frameworks:

• Herbicide / Agent Orange: 304 cases combined (304 herbicide + 88 Agent Orange tags, with substantial overlap in coding)
• Burn-pit (PACT Act): 46 cases
• Camp Lejeune: 40 cases
• Radiation: 19 cases
• Gulf War: 6 cases

Here's the structural quirk that veterans often miss: the Agent Orange and PACT Act presumptive lists cover prostate cancer, not BPH or chronic prostatitis specifically. When a non-cancer prostate condition appears in our presumptive subset, it's usually one of three patterns:

Pattern A: Cancer history with non-cancer post-treatment residuals. The veteran was previously diagnosed with service-connected prostate cancer (Agent Orange or PACT Act presumptive), completed treatment, and now has chronic urinary symptoms or BPH-type residuals. The non-cancer prostate condition is rated as residuals of the cancer.

Pattern B: Camp Lejeune water exposure for non-cancer prostate conditions. The Camp Lejeune presumptive framework under 38 USC § 1710(e) covers bladder cancer and certain other urinary conditions but doesn't directly list BPH. Veterans claim under § 3.310 secondary service connection, arguing the prostate condition is secondary to or aggravated by other Camp Lejeune presumptive conditions.

Pattern C: Herbicide exposure with prostate dysfunction arguments. Some veterans claim BPH or chronic prostatitis as related to herbicide exposure under direct (non-presumptive) service connection, citing the same scientific framework that supports the cancer presumption. The Board has been inconsistent in accepting this theory.

The 57.9 percent presumptive grant rate reflects the fact that most presumptive-coded cases in this subset are pattern A (cancer history with residuals) where the underlying service connection was already established through the cancer presumption.

When Service Connection Goes Through the Cancer Side

Veterans previously diagnosed and treated for service-connected prostate cancer often develop chronic urinary symptoms post-treatment. Surgical residuals from radical prostatectomy can include voiding dysfunction, erectile dysfunction, and urinary stricture. Radiation residuals can include radiation cystitis, urinary urgency, and proctitis.

When these residuals develop, the rating analysis stays within the genitourinary chapter. The cancer rating itself drops from 100 percent to the residuals-based level six months after treatment (under DC 7528). Any additional non-cancer prostate conditions that develop subsequently are usually rated as additional residuals rather than as separately service-connected conditions, since they trace back to the same underlying service-connected pathology.

For veterans whose cancer was service-connected presumptively, this cascade is structurally favorable. The presumption did the connection work once. Subsequent residuals don't need additional service-connection development.

The Aggravation Pathway for Pre-Service BPH

Some veterans entered service with mild prostate symptoms that aren't formally documented at entrance. They develop more significant BPH or chronic prostatitis during service. The question becomes whether service aggravated a pre-existing condition.

Under 38 CFR § 3.306, a pre-existing condition is presumed to have been aggravated by service if there was an increase in disability during service, unless the increase was due to the natural progression of the disease. The Allen v. Brown framework (Allen v. Brown, 7 Vet. App. 439 (1995)) governs how aggravation is analyzed.

For BPH specifically, the natural-progression question is medically complicated. BPH develops in roughly half of men over age 50, and the prostate enlarges progressively with age regardless of military service. Distinguishing "aggravated by service" from "naturally progressed during service" requires clinical evidence the Board has historically been skeptical of accepting.

In our dataset, aggravation claims for non-cancer prostate conditions are rare and underperform direct claims. The Allen v. Brown framework is technically available but doesn't usually produce wins for BPH.

What Wins Non-Cancer Prostate Claims at the Board

A few patterns we see consistently in granted cases:

Documented in-service symptoms or treatment. Service treatment records showing urinary symptoms, BPH diagnosis, or chronic prostatitis treatment during active duty establish the direct service connection foundation. Veterans who entered service asymptomatic and developed documented BPH or chronic prostatitis during service have a clean path under direct service connection.

Continuity of treatment post-service. Medical records showing ongoing urological treatment, BPH medications (alpha-blockers, 5-alpha reductase inhibitors), or chronic prostatitis management establish the condition's chronicity and ongoing severity.

Symptom-specific documentation. The rating analysis depends on which symptom is predominant. Voiding dysfunction needs documentation of incontinence and absorbent material use. Urinary frequency needs voiding interval documentation. Urinary tract infection needs treatment records for recurrent infections. The C&P examination and the treating urologist's records need to engage with the specific symptom category that supports the rating tier sought.

Secondary theory through prostate cancer. For veterans with previously service-connected prostate cancer, claiming subsequent non-cancer prostate symptoms as residuals or as separately service-connected secondary conditions is often the structurally cleaner path than trying to establish independent service connection.

Camp Lejeune adjacency claims. Veterans with qualifying Camp Lejeune service may be able to claim prostate conditions as related to other presumptive conditions covered under that framework, particularly where the medical record documents a downstream relationship.

Bottom Line

Non-cancer prostate conditions rate under 38 CFR § 4.115b DC 7527, which routes the rating to whichever genitourinary symptom category is predominant: voiding dysfunction, urinary frequency, or urinary tract infection. In our BVA dataset of 960 cases, the grant rate is 48.1 percent. The presumptive lane grants at 57.9 percent, driven mostly by veterans with previously service-connected prostate cancer whose non-cancer prostate conditions are treated as residuals. Direct service connection grants at 47.5 percent for veterans with in-service onset documentation. The largest denial reason is "severity insufficient": the rating tier criteria not being met for the rating sought, particularly for voiding dysfunction where absorbent material use frequency is the dispositive variable. Strong nexus opinions grant at 95.3 percent versus 0 percent for weak nexus, the steepest opinion-quality cliff we track in the urological cluster. For veterans with service-connected prostate cancer history, claiming subsequent prostate conditions as residuals or secondary is structurally favorable. For veterans without that foundation, the direct lane requires clean in-service documentation and engagement with the specific symptom-category criteria in 38 CFR § 4.115a.

Methodology and Limitations

• Data source: 38 CFR § 4.115b DC 7527 (prostate gland injuries, infections, hypertrophy, postoperative residuals), 38 CFR § 4.115a (genitourinary residuals rating criteria), 38 CFR § 3.310 (secondary service connection), 38 CFR § 3.306 and Allen v. Brown framework for aggravation, 38 USC § 1116 (Agent Orange), 38 USC § 1710(e) (Camp Lejeune), and Claim Raven's analysis of BVA decisions tagged with non-cancer prostate conditions as the primary issue.
• Sample size: 960 BVA decisions involving non-cancer prostate conditions as the primary condition. Outcomes split granted 48.1% (462), denied 38.5% (370), remanded 13.3% (128). Connection-type, nexus-quality, denial-reason, and rating-tier breakdowns are coded from the Board's discussion in each decision.
• Limitations: The dataset captures BVA-level decisions and isn't representative of all non-cancer prostate claims filed with VA. The distinction between cancer and non-cancer prostate conditions in our coding is based on the primary condition tag; some cases involve both diagnoses with the rating analysis crossing between DC 7527 and DC 7528. The Camp Lejeune presumptive framework continues to be litigated and expanded, and current regulatory text controls over older interpretations. These observations describe BVA patterns and are not predictions of individual outcomes, and Claim Raven is data analysis, not legal, medical, or VA-accredited advice.